Hims & Hers Snaps EPS Losing Streak but Shares Still in Free Fall
Hims & Hers Health (NYSE: HIMS) delivered a beat on both earnings and profitability in Q4 2025, though a soft 2026 revenue guidance is keeping the stock under pressure after a sharp year-to-date selloff. The company posted EPS of $0.08,…
Hims & Hers Health (NYSE: HIMS) delivered a beat on both earnings and profitability in Q4 2025, though a soft 2026 revenue guidance is keeping the stock under pressure after a sharp year-to-date selloff.
The company posted EPS of $0.08, topping the $0.05 consensus estimate by 60%. Q4 revenue came in at $617.8 million, up 28.4% year-over-year and in line with analyst expectations. Adjusted EBITDA reached $66 million at an 11% margin, landing above the high end of the company’s own guidance range of $55 million to $65 million. For the full year, revenue totaled $2.35 billion, up 59% year-over-year.
The EPS beat snaps a streak of four consecutive quarterly misses and marks a clear profitability improvement from Q3’s $0.06 reported EPS. However, the GLP-1 regulatory overhang remains the defining risk: the FDA’s resolution of the semaglutide shortage has restricted Hims’s compounded weight-loss offerings, a key growth driver. Negotiations with Novo Nordisk over distributing branded Wegovy on the platform remain ongoing with no definitive agreement.
For 2026, management’s revenue and adjusted EBITDA guidance came in below analyst expectations, which may explain why the stock is down 78% year-to-date to $14.50 in Tuesday’s premarket despite the earnings beat. Retail sentiment on Reddit shifted sharply bullish post-earnings, with a r/wallstreetbets YOLO post accumulating 308 upvotes and 383 comments. Whether the Novo Nordisk partnership materializes and how the GLP-1 product transition affects subscriber growth through mid-2026 remain key variables for the company’s outlook.
Contact [email protected] for any questions or corrections.
Trey has been an editor and author at 24/7 Wall St. for more than a decade, where he has published thousands of articles analyzing corporate earnings, dividend stocks, short interest, insider buying, private equity, and market trends. His comprehensive coverage spans the full spectrum of financial markets, from blue-chip stalwarts to emerging growth companies.
Beyond 24/7 Wall St., Trey has created and edited financial content for Benzinga and AOL's BloggingStocks, contributing additional hundreds of articles to the investment community. He previously oversaw the 24/7 Climate Insights site, managing editorial operations and content strategy, and currently oversees and creates content for My Investing News.
Trey's editorial expertise extends across multiple publishing environments. He served as production editor at Dearborn Financial Publishing and development editor at Kaplan, where he helped shape financial education materials. Earlier in his career, he worked as a writer-producer at SVE. His freelance editing portfolio includes work for prestigious clients such as Sage Publications, Rand McNally, the Institute for Supply Management, the American Library Association, Eggplant Literary Productions, and Spiegel.
Outside of financial journalism, Trey writes fiction and has been an active member of the writing community for years, overseeing a long-running critique group and moderating workshop sessions at regional conventions. He lives with his family in an old house in the Midwest.
